Smoking Cessation Treatment for Methadone Maintenance Patients
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
Patients in substance abuse treatment smoke four times more than non-substance abusers, and
suffer high rates of tobacco-related disease and death. While many quit smoking treatments
exist that have been shown to help non-substance abusers quit smoking, little is known about
what treatments work for patients in substance abuse treatment. The drug varenicline
(Chantix) has been shown to be more effective at helping people quit smoking than nicotine
replacement therapy, bupropion or placebo. However, varenicline has not yet been studied in
patients in substance abuse treatment. The study aims to evaluate the feasibility,
effectiveness and safety of varenicline, in combination with counseling, in methadone
maintained smokers. It also aims to evaluate the link between quitting smoking and alcohol
and illicit drug use in methadone maintained smokers. We hypothesize that participants
receiving varenicline will have higher abstinence from smoking than participants receiving
placebo and that participants taking varenicline will not have significantly more adverse
reactions than were described in the general population in other studies. We also hypothesize
that compared to continued smokers, tobacco abstainers will be more likely to be abstinent
from alcohol or illicit drugs.
Phase:
Phase 4
Details
Lead Sponsor:
Albert Einstein College of Medicine Albert Einstein College of Medicine of Yeshiva University